Hematopoietic cell transplantation (HCT) is a life-saving treatment for patients with high-risk hematological malignancies. Prognostic measures to determine fitness for HCT are needed to inform decision-making and interventions. VO 2peak is obtained by measuring gas exchange during cycle ergometry and has not been studied as a prognostic factor in HCT. Thirty-two autologous and allogeneic HCT patients underwent VO 2peak and 6 Minute Walk (6MW) testing before HCT, and provided weekly symptom and health-related quality of life (HRQOL) assessments before HCT and concluding at Day 100. Twenty-nine patients completed pre-HCT testing. Pre-HCT VO 2peak was positively correlated with pre-HCT 6MW (r ¼ 0.65, Po0.001) and negatively correlated with number of chemotherapy regimens and months of chemotherapy. Patients with lower VO 2peak reported higher symptom burden and inferior HRQOL at baseline and during early post-HCT period. Patients with pre-HCT VO 2peak o16 mL/kg/min had higher risk of mortality post HCT (entire cohort: hazard ratio (HR) 9.1 (1.75-47.0), P ¼ 0.01; allogeneic HCT patients only: HR 6.70 (1.29-34.75), P ¼ 0.02) and more hospitalized days before Day 100 (entire cohort: median 33 vs 19, P ¼ 0.003; allogeneic HCT patients only: median 33 vs 21, P ¼ 0.004). VO 2peak pre-HCT is feasible and might predict symptom severity, HRQOL and mortality. Additional studies are warranted.
INTRODUCTION
For patients with life-threatening hematological diseases, hematopoietic cell transplantation (HCT) offers the possibility of extended survival relative to standard conventional treatments. 1 The benefits of HCT are counterbalanced by the risk of treatmentrelated toxicity. Prognostic measures are needed to inform clinician and patient decision-making and to limit treatmentrelated risk. Direct cardiopulmonary fitness assessments such as VO 2peak are now available but have not yet been studied.
Myeloablative allogeneic HCT has been associated with a 30-40% risk of treatment-related mortality (TRM). 2 Reduced intensity conditioning HCT is offered to older individuals and patients with comorbid illness, but this technique is still associated with a 20-30% risk of TRM. 3 Autologous HCT in older patients has been associated with a TRM risk exceeding 10%. 4 Subsets of patients after all types of transplants experience late health-related quality of life (HRQOL) deficits and functional impairment; 5 this effect is variable with other subgroups experiencing preserved patient-reported outcomes (PROs), relative to normative values. 6 Investigators and clinicians have attempted to determine who is 'fit' for transplant to inform pre-HCT counseling, selection of suitable HCT candidates and identification of vulnerable HCT recipients at risk for treatment-related complications. 7 Age remains the most commonly used surrogate variable for HCT 'fitness,' with specific measures of end-organ function also being used. Newer measures incorporate disease risk, 8 comorbidities (for example, HCT-CI 9 ) and other aggregations of pre-HCT variables (for example, EBMT risk score 10 ). The clinician-assessed Karnofsky Performance Status (KPS) has also demonstrated prognostic value. 11 None of these assessments include cardiorespiratory fitness.
In healthy individuals and in other disease states, direct measurement of functional capacity and cardiorespiratory fitness using the 6 Minute Walk (6MW) or cycle ergometry (VO 2peak ) is feasible and has prognostic value for survival. [12] [13] [14] These techniques have not been studied in patients planning to undergo HCT. Studies have demonstrated the feasibility of VO 2peak measurement in survivors of allogeneic HCT, [15] [16] [17] and the potential benefit of exercise intervention in ameliorating functional decline. [18] [19] [20] These data suggest a role for investigating VO 2peak measurement (and potentially, multimodality intervention to improve functional capacity) before the anticipated physiological stress of HCT.
The purpose of this study was to determine the extent to which VO 2peak is a clinically useful, prognostic indicator for patients undergoing HCT. The feasibility of obtaining pre-HCT VO 2peak values was of interest, as well as the associations of VO 2peak with other clinician-and patient-reported measures of functional capacity, symptomatic treatment toxicity and HRQOL.
MATERIALS AND METHODS Patients
Patients were approached for enrollment if they were over 18 years of age, could read English and were able to provide informed consent. Three planned cohorts, with targeted enrollment of 10 patients per cohort, included patients undergoing planned autologous HCT, full intensity allogeneic HCT or reduced intensity conditioning allogeneic HCT.
Sequential prospective transplant recipients were recruited, and only patients with baseline EKG abnormalities (N ¼ 1) were excluded from participation. Patients interested in enrolling were asked to sign an informed consent approved by the UNC Biomedical Institutional Review Board.
Enrolled patients underwent cardiopulmonary assessment (VO 2peak , 6MW and dual energy X-ray absorptiometry) and PRO measurement before conditioning chemotherapy. Clinical exercise testing was performed by an exercise physiologist under medical supervision. PRO measures were completed weekly through Day 100.
Minute Walk
The 6MW distance was evaluated on the BMT unit at UNC Cancer Hospital, and in accordance with procedures of the American Thoracic Society. 21 A hallway on the BMT unit was marked in 5-m increments in a straight line extending for 30 m. Patients were instructed to perform laps from the 0-to 30-m mark and back again for a total of 6 min. Patients were instructed that goal of the test was to walk as far as possible. Upon completion of the test, the heart rate was again obtained. Following completion of the 6MW test, patients were provided with water and instructed to rest for 10 min before moving to VO 2peak testing.
VO 2peak testing
Cardiopulmonary function was evaluated using an exercise test with gas exchange for the assessment of peak oxygen uptake (VO 2peak ). The cardiopulmonary exercise test was performed on the BMT unit at UNC Cancer Hospital, in a separate room not used for patient-care activities, with a portable cycle ergometer (Monark 828E, Goteborg, Sweden). Expired gases were measured using a portable mobile metabolic system (K4b; 2 Cosmed, Rome, Italy) that can be easily transported and calibrated as needed. Performing tests on the BMT unit achieved maximal patient convenience while ensuring availability of nearby medical support if needed at any time during the test. Cycle ergometry was performed under the supervision of a trained exercise physiologist with a physician standing by. Immediately before beginning the test, recent medical records were re-reviewed and baseline vital sign measurements were obtained, including blood pressure, resting heart rate and oxygen saturation, as specified in pre-fitness testing guidelines from the American College of Sports Medicine. 22 Patients were fitted with masks for gas exchange analysis, and the cycle ergometer was adjusted for each patient, after which a resting metabolic measurement was obtained for approximately 5 min while patients sat quietly on the cycle ergometer. This ensured a minimum of 15 minutes of rest between 6MW and VO 2peak testing. Patients were then instructed to pedal at a cadence of 50 r.p.m. Starting at 25 W, workload was increased in 5-20 watts/min increments. VO 2peak was defined as: volitional exhaustion, achievement of respiratory exchange ratio 41.0, symptom limitation (for example, chest pain, dizziness, nausea and abnormal heart-rate response), or a decrease or plateau in heart rate or VO 2 (mL/kg/min) with increased workload. The VO 2peak test lasted approximately 8 min on average. Following achievement of VO 2peak , subjects remained pedaling on the cycle ergometer without resistance until the heart rate was below 110 b.p.m., at which time subjects were assisted off the ergometer and seated while continuing to rest. After 10 min of rest, vital signs were re-checked and patients were dismissed from the test.
Body composition
Body composition was assessed by dual energy X-ray absorptiometry (Hologic, Bedford, MA, USA). The scan was administered by a trained clinician at UNC Hospitals Translational Research Center. Body fat (kg), percent body fat, bone mineral density (g/cm 2 ), bone mineral content (g), lean mass (kg) and total mass (kg) were recorded.
PRO measures
The National Cancer Institute's (NCI's) PRO-Common Terminology Criteria for Adverse Event (CTCAE) is a measurement system designed to gather symptomatic adverse events by patient self-report. PRO-CTCAE items are intended to be complementary to items in the NCI's CTCAEs, an existing lexicon of clinician-reported adverse events required for use in all NCIsponsored trials (http://outcomes.cancer.gov/tools/pro-ctcae.html). The PRO-CTCAE library is comprised of 124 items assessing various attributes (for example, presence, frequency, severity and interference with daily activities) of 80 symptoms that are represented in the CTCAE (version 4). Only PRO-CTCAE items measuring symptom severity were selected for administration. PRO-CTCAE severity items ask patients to rate the worst severity of a specific symptom in the past 7 days, using five response choices (none, mild, moderate, severe or very severe). Thirty-four symptom severity questions (see Supplementary Appendix) thought to be relevant to patients undergoing HCT were selected from the PRO-CTCAE item library by the study team and administered weekly. An overall weekly symptom burden score was calculated by summing the score for each symptom question (range 0-4) to obtain a total score ranging from 0 to 136. Higher scores represent greater symptom burden (http://outcomes.-cancer.gov/tools/pro-ctcae.html).
National Institutes of Health's Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health scale is a 10-question HRQOL assessment that includes questions about quality of life, general functioning, physical, mental, social and overall health, symptoms of pain, fatigue, and depression and anxiety. 23 A Physical Health score and Mental Health score were derived from the PROMIS Global Health scale, each using four separate questions. The scores were calibrated on a T-score metric normed with a general population sample with a mean of 50 and a s.d. of 10. 23 Higher scores reflect better HRQOL. Though minimally important differences have not been estimated for this scale in this patient population, prior studies using PROMIS-Cancer in advanced cancer patients estimate minimally important difference interquartile ranges of three to five points for fatigue, anxiety and depression, and four to six points for pain and physical functioning. 24 The PROMIS Global Health scale was administered weekly to patients (see Supplementary Appendix).
Patients were invited to complete all surveys electronically, though paper-and-pencil versions of each survey were available. 25 Electronic surveys were administered using a HIPAA-compliant survey tool provided by Qualtrics, Inc. (Provo, UT, USA). Surveys were completed using studyprovided electronic tablets or on participants' personal electronic devices.
Statistical methods
Feasibility was defined as enrollment of 460% of approached patients. Medians and ranges are presented for most continuous measures and compared using Wilcoxon rank-sum tests. Spearman's correlation coefficients are used to measure correlations between pre-HCT VO 2peak and other pre-HCT variables. To evaluate associations of pre-HCT functional testing and mortality, univariable Cox regression models are used, and hazard ratios (HRs), along with 95% confidence intervals, are reported. VO 2peak was analyzed as both a continuous and a categorical variable with a cutpoint of 416 mL/kg/min, based on prior literature associating a value of 15.4 mL/kg/min with functional independence and prognosis in solid tumor malignancies.
14,26 A Kaplan-Meier plot provides visual representation of the association between impaired vs comparatively preserved pre-HCT VO 2peak and mortality. All analyses were performed using SAS statistical software, version 9.2 (SAS Institute, Cary, NC, USA).
RESULTS

Patients
Among 47 patients approached for enrollment onto the study, 32 (68%) agreed to participate and were enrolled into three cohorts (10 autologous HCT recipients with either melphalan or BEAM conditioning, 11 full intensity allogeneic HCT recipients usually with full dose of BU and fludarabine and 11 reduced intensity allogeneic HCT recipients usually with reduced dose of BU and fludarabine). Median age at time of transplantation for the entire cohort was 57.6 years. A majority had intermediate or advanced disease 10 and one or more comorbid illnesses. The median ECOG Performance Status was 1 (range 0-2) and median Karnofsky Performance Status was 90 (range 60-100). Sample demographic and baseline characteristics are presented in Tables 1 and 2 .
Feasibility VO 2peak and 6MW were completed before HCT in 29 (91%) patients with no adverse events. Three patients did not start or complete VO 2peak testing: one with previous lower limb amputation, one with knee pain during bicycle motion and one patient participated in PRO measurement but was excluded from exercise testing per clinician discretion because of baseline EKG abnormalities.
The median weekly percentage of participants who completed the patient-reported surveys was 100% in all cohorts from the start of conditioning to hospital discharge. The median completion rate for weekly reporting was 100% through D100 for the autologous and reduced intensity allogeneic cohorts, and 80% for the full intensity allogeneic cohort.
Pre-transplant fitness and other pre-HCT variables Results of exercise testing and dual energy X-ray absorptiometry scans are presented in Table 1 . The median VO 2peak for the entire group was 20.9 mL/kg/min (range 9.3-35.4 mL/kg/min). Eight (28%) patients had a VO 2peak p16 mL/kg/min. Patients walked a median of 480 m (range 305-690 m). Table 3 shows correlations of pre-HCT VO 2peak with other pre-HCT variables. Pre-HCT VO 2peak was strongly positively correlated with pre-HCT 6MW distance (r ¼ 0.65, Po0.001) and moderately negatively correlated with number of chemotherapy regimens received (r ¼ À 0.43, P ¼ 0.02) and months of chemotherapy received before HCT (r ¼ À 0.43, P ¼ 0.03). There was also moderate correlation between VO 2peak and time from diagnosis to transplant (r ¼ À 0.27, P ¼ 0.16); this was not statistically significant. There were no statistically significant associations between VO 2peak and age, HCT-CI score or EBMT score. VO 2peak was not associated with disease risk by Wilcoxon rank-sum test (P ¼ 0.21) but was associated with a pre-HCT Karnofsky performance status score o90 (P ¼ 0.006).
Relationship of VO 2peak with PROs Scores for patient-reported data are depicted in Figure 1 . Patients with VO 2peak p16 mL/kg/min had higher total symptom severity scores, and lower physical and mental health scores, at baseline than patients with VO 2peak 416 mL/kg/min. These differences in total symptom burden and physical and mental health persisted across the study. For total symptom scores, differences between patients with VO 2peak p16 vs 416 mL/kg/min were statistically significant at baseline (8.0 vs 24.0, P ¼ 0.02) and Day 0 (18.0 vs 34.0, P ¼ 0.01). Significant differences between low and high VO 2peak groups were seen in physical health scores at baseline (54.1 vs 42.3, P ¼ 0.003) and Day 0 (47.7 vs 37.4, P ¼ 0.05). Differences in mental health scores between groups with preserved vs impaired cardiorespiratory fitness were significant at baseline (53.3 vs 50.8, P ¼ 0.01) and Day 100 (53.3 vs 41.1, P ¼ 0.02). These differences are likely to be clinically meaningful, based on prior data regarding minimally important differences in advanced cancer patients using other PROMIS surveys. 25 Relationship of VO 2peak with clinical outcomes Lower VO 2peak was significantly associated with a higher risk of post-HCT mortality when analyzed as a continuous variable, with one unit represented as 1 mL/kg/min (entire cohort: HR 1.18 (1.03-1.35), P ¼ 0.02; allogeneic HCT patients only: HR 1.13 (1.01-1.27), P ¼ 0.03). A VO 2peak o16 mL/kg/min was significantly associated with a higher risk of mortality after HCT (entire cohort: HR 9.1 (1.75-47.0), P ¼ 0.01; allogeneic HCT patients only: HR 6.70 (1.29-34.75), P ¼ 0.02) (Figure 2) . Each 100-m decrease in pre-HCT 6MW was also associated with a higher risk of mortality, especially in allogeneic HCT patients (entire cohort: HR 2.01 (0.95-4.25), P ¼ 0.07; allogeneic HCT patients only: HR 2.98 (1.36-6.54), Po0.01). Borderline significant associations with higher post-HCT mortality were seen for each 10 kg decrease in pre-HCT lean mass (entire cohort: HR 1.91 (0.97-3.77), P ¼ 0.06; allogeneic HCT patients only: HR 1.56 (0.82-2.97), P ¼ 0.18) ( Table 4) . Of the three early deaths related to TRM that were observed in this sample, two occurred among patients with VO 2peak p16 mL/kg/min, and the third occurred in a patient unable to perform VO 2peak testing because of a physical handicap. Lower VO 2peak was significantly associated with longer length of stay during the initial transplant hospitalization (median 25 days for patients with VO 2peak p16 vs 15 days for patients with VO 2peak 416 mL/kg/min, P ¼ 0.01) and a higher number of hospitalized days before Day 100 (33 for patients with VO 2peak p16 vs 19 for patients with VO 2peak 416 mL/kg/min, P ¼ 0.003).
DISCUSSION
Our study provides preliminary evidence that pre-transplant exercise testing with cycle ergometry and 6MW is feasible in patients receiving HCT. This testing predicts mortality risk, physical and mental health status, symptomatic treatment toxicity and hospital days.
Two patients in our study were unable to attempt exercise testing because of physical limitations; there were no safety issues or adverse events during testing. Under no circumstances did testing hinder or delay the receipt of intended HCT therapy. These data confirm the feasibility and safety of VO 2peak and 6MW before HCT. The median VO 2peak for our group of 20.9 mL/kg/min compares with a VO 2peak of 22.8 mL/kg/min in independently living 55-86-year-old men. 26 Patients in our cohort walked a pre-HCT median of 480 m (range 305-690 m), compared with a reported mean 6MW distance of 575.8 m in other patients with hematological malignancies, 27 and a mean of 384 m in post-allogeneic HCT patients. 21 The 6MW distance has demonstrated prognostic value in other clinical populations, including patients with chronic obstructive pulmonary disease or heart failure, older adults and those with solid tumors, hematological malignancies and post-transplant survivors. [28] [29] [30] Cardiopulmonary exercise testing has demonstrated predictive ability in advanced lung and breast cancer. 12, 13 Functional capacity impairments in patients with chronic GVHD have also been shown to mediate adverse changes in post-HCT functional performance associated with symptom burden. 31 There are limited data regarding 6MW in HCT, 32 and no data that we are aware of that explore the feasibility or prognostic value of cardiopulmonary testing in patients planning to undergo HCT. Muffly et al. 33 recently reported on the use of a comprehensive geriatric assessment before allogeneic transplant, which incorporated a 'Frailty Index' that included walk speed and grip strength. Impairment in these two measures were demonstrated by 28% and 22% of patients, respectively, though raw measurements and association with outcomes were not reported in this manuscript. Deschler et al. 34 performed geriatric and quality of life assessments, including Timed Up and Go tests, on 195 older patients with myelodysplastic syndrome and AML. In their study, 75 patients went on to intensive chemotherapy/ hematopoietic cell transplantation. A Timed Up and Go test results of 430 s were significantly prognostic for mortality in the nonintensive treatment group (HR 3.30, 2.00-5.42, Po0.0001), and not specifically reported in the transplant group.
In our population, VO 2peak and the 6MW distance were strongly positively correlated, suggesting that these tests may measure similar characteristics of patient functional capacity. It is possible that 6MW and VO 2peak could prove to be somewhat interchangeable, particularly for patients who cannot complete maximal exercise testing because of symptom limitations. Future work could identify a stepped evaluation; patients below a certain threshold of 6MW distance are referred for VO 2peak testing to more precisely characterize risk. The value of the 6MW is especially important because it is low cost, reliable and available in most clinical settings, including those without trained exercise physiology personnel or specialized equipment.
The pattern of longitudinal PRO data between those with impaired vs preserved VO 2peak suggests that both groups experience a similar trajectory of acute conditioning-related symptomatic toxicities and unfavorable changes in physical HRQOL across the first 30 days post transplant. Patients with VO 2peak p16 mL/kg/min approached a particularly high absolute level of overall symptom burden at the height of conditioning- related toxicity; whether this level of patient-reported toxicity correlates with an underlying critical physiological threshold of stress tolerance warrants further study. Interestingly, between Day þ 30 and Day þ 100, the two groups appear to have diverging patterns in their recovery. Those with a VO 2peak 416 mL/kg/min experience a gradual improvement in symptom severity and physical health, and sustain preserved levels of mental health, such that by Day þ 100, they have returned to their pre-transplant baseline status. In contrast, those with VO 2peak p16 mL/kg/min tended to have gradually worsening symptom burden, limited improvement in physical health and marked decrements in mental health status. We acknowledge that these trends must be interpreted with caution because of missing PRO data from morbidity and mortality in the p16 group. Had data from all participants been available, it is conceivable that observed differences between the two trajectories could have been even larger. Pre-transplant exercise testing appears to define a group of patients who might benefit from intensive targeted rehabilitative interventions designed to improve clinical and functional outcomes and well being. Future studies to examine this hypothesis appear warranted.
Patients with reduced pre-transplant VO 2peak experience higher symptom burden, worse HRQOL and a greater likelihood of death following HCT. As a possible explanation, VO 2peak may reflect pre-HCT physiological reserve. Furthermore, VO 2peak was most strongly correlated in our study with amount of prior chemotherapy. Patients exposed to a level of further physiological 'insult'-type of transplant, conditioning regimen intensity, chemotherapy metabolism and/or other factors-are at risk of approaching a physiological tipping point post HCT, after which complications such as acute and chronic GVHD (perhaps related to enhanced activation of innate immunity), 35 opportunistic infection, side effects of immunosuppressive medication and, possibly, disease relapse become more likely. Autologous HCT recipients are at lower risk of many of these complications, though other outcomes such as long-term HRQOL, rehospitalization and even TRM are possibly relevant. Those recipients with impaired pre-HCT physiological reserve are perhaps at greater risk. Our results also identify HCT recipients with impaired cardiorespiratory fitness as a group who are potentially at risk for persistently elevated symptom burden and delays in recovery of HRQOL. Critically, PROs provide a new way to measure this longitudinal toxicity.
Several caveats must be considered in interpreting the results of these analyses. Our small sample size precluded our ability to construct multivariable models, and our observations should be replicated in larger samples. Future studies should be powered to permit adjustment of VO 2peak for age, gender and lean body mass, and examine whether 6MW distance or heart-rate response to exercise testing have comparable predictive validity. In addition, our PRO assessments from Day 30 to Day 100, particularly among patients with VO 2peak p16 mL/kg/min, were limited by patient drop-out from morbidity and mortality; we were thus unable to determine if differences at Day 100 in symptom burden were statistically significant.
Although acknowledging how these limitations may have affected the outcomes, our results demonstrate the feasibility of incorporating assessments of functional capacity and cardiorespiratory fitness into baseline HCT evaluation, and suggest a number of hypotheses for future research. Studies in larger populations are needed to further evaluate the prognostic utility of pre-HCT VO 2peak for post-HCT outcomes, including mortality and other patient-centered adverse outcomes such as symptom burden, functional disability and HRQOL impairment. Our results support a conclusion that objective pre-transplant evaluation of cardiorespiratory fitness, together with PRO assessments, predict important post-transplant outcomes. If replicated in larger samples, these pre-transplant evaluations could be applied to define vulnerable subgroups of patients who would benefit from targeted intervention. These interventions could occur in the pre-HCT period (for example, tailoring intensity of pre-HCT therapy or an exercise training intervention to improve VO 2peak ) and/or in the early post-HCT period (for example, aggressive symptom management, intensive rehabilitation and psychosocial support), thus improving transplantation outcomes in vulnerable individuals.
